Sandoz Confirms Launch Of Humira Rival In Canada
Introduction Of Hyrimoz Comes As Other Adalimumab Biosimilars Expected
Sandoz has confirmed the launch of its Hyrimoz biosimilar rival to Humira in Canada, with other biosimilars firms having also set their sights on a mid-February launch.
You may also be interested in...
The first biosimilar approval stemming from Alvotech’s collaboration with JAMP Pharma in Canada has arrived, with the firms’ Simlandi (adalimumab) biosimilar version of AbbVie’s higher-strength Humira. Celltrion has also announced an approval from Health Canada.
Sandoz Canada has taken another “important step as we pursue our ambition to become the leading biosimilars and generics company” with the launch of biosimilar enoxaparin.
Sandoz is determined to be “first in and last out” on key product opportunities, while also seeking to strengthen its pipeline through deals and partnerships, the company’s new North America head, Keren Haruvi, tells Generics Bulletin in an exclusive interview.